Ultragenyx Pharmaceutical Inc Dojolvi US FDA Approval Call Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the Dojolvi U.S. FDA approval call. (Operator Instructions)
I would now like to hand the conference over to your speaker, Ms. Danielle Keatley. Ms. Keatley, the floor is yours.
Thank you. Good afternoon, and welcome to the Ultragenyx conference call to discuss today's U.S. FDA approval of Dojolvi. We've issued a press release detailing the approval, which you can find on our website at ultragenyx.com. I'm Danielle Keatley, Senior Director of Investor Relations.
Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Erik Harris, Chief Commercial Officer; and Camille Bedrosian, Chief Medical Officer.
I'd like to remind investors that this call will include forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 including, but not limited to, types of statements
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |